Rinsho K, Uchida K, Samma S, Oyasu R
Department of Pathology, Northwestern University Medical School, Chicago, Illinois 60611.
J Cancer Res Clin Oncol. 1988;114(3):231-4. doi: 10.1007/BF00405827.
We previously demonstrated that repeated intravesical instillation of DFMO, an irreversible inhibitor of ornithine decarboxylase, inhibits (or retards) urinary bladder carcinogenesis in rats. The present investigation was conducted to determine if high intraluminal concentration of DFMO alters initiation by MNU and to determine if DFMO inhibition is due to arrest of tumor progression or simply retardation of the tumor development. Results showed that the inhibitory effects demonstrated by DFMO treatment during the early phase of study disappeared as the observation period was extended. Failure to suppress tumor development might be due to failure to control intracellular polyamine levels below the critical level and this failure in turn might be due to the rapid fall of intravesical DFMO concentration following instillation.
我们之前证明,反复膀胱内灌注鸟氨酸脱羧酶的不可逆抑制剂二氟甲基鸟氨酸(DFMO)可抑制(或延缓)大鼠膀胱癌的发生。本研究旨在确定高腔内浓度的DFMO是否会改变N-甲基-N-亚硝基脲(MNU)的启动作用,并确定DFMO的抑制作用是由于肿瘤进展停滞还是仅仅是肿瘤发展的延缓。结果表明,随着观察期的延长,DFMO治疗在研究早期所显示的抑制作用消失。未能抑制肿瘤发展可能是由于未能将细胞内多胺水平控制在临界水平以下,而这种失败反过来可能是由于灌注后膀胱内DFMO浓度迅速下降所致。